Literature DB >> 24444436

How do values shape technology design? An exploration of what makes the pursuit of health and wealth legitimate in academic spin-offs.

Pascale Lehoux1, Geneviève Daudelin, Myriam Hivon, Fiona Alice Miller, Jean-Louis Denis.   

Abstract

By actively supporting cooperation between academia, clinical settings and industry, several policy initiatives assume that the two policy agendas of health and wealth can be reconciled through the development of health technology. Our goal in this article is to shed light on the way the concurrent pursuit of health and wealth operates in practice by examining the valuation schemes, actions and decisions that shaped technology development in three Canadian spin-offs. Drawing on the sociology of judgement, our analytical framework conceives of technology development as a purposive collective action that unfolds in a normatively heterogeneous context (one pervaded with both corporate and public service mission values and norms). Our qualitative empirical analyses explore four valuation schemes and their corresponding regimes of engagement that characterise why and how technology developers commit themselves to addressing certain clinical, interactional, organisational and economic concerns throughout the development process. Our discussion suggests that the ability to reconcile health and wealth goals is to be found in the moral repertoires that provide meaning to, and render coherent technology developers' participation in corporate activities driven by economic growth.
© 2014 The Authors. Sociology of Health & Illness © 2014 Foundation for the Sociology of Health & Illness/John Wiley & Sons Ltd.

Keywords:  R&D; academic spin-offs; commercialisation of research; health technology; innovation policy; sociology of innovation

Mesh:

Year:  2014        PMID: 24444436     DOI: 10.1111/1467-9566.12097

Source DB:  PubMed          Journal:  Sociol Health Illn        ISSN: 0141-9889


  5 in total

1.  Providing Value to New Health Technology: The Early Contribution of Entrepreneurs, Investors, and Regulatory Agencies.

Authors:  Pascale Lehoux; Fiona A Miller; Geneviève Daudelin; Jean-Louis Denis
Journal:  Int J Health Policy Manag       Date:  2017-09-01

2.  The Bright Elusive Butterfly of Value in Health Technology Development Comment on "Providing Value to New Health Technology: The Early Contribution of Entrepreneurs, Investors, and Regulatory Agencies".

Authors:  Trisha Greenhalgh; Nick Fahy; Sara Shaw
Journal:  Int J Health Policy Manag       Date:  2018-01-01

3.  Why is repositioning public health innovation towards a social paradigm necessary? A reflection on the field of public health through the examples of Ebola and Covid-19.

Authors:  Marietou Niang; Sophie Dupéré; Hassane Alami; Marie-Pierre Gagnon
Journal:  Global Health       Date:  2021-04-14       Impact factor: 4.185

4.  How does venture capital operate in medical innovation?

Authors:  P Lehoux; F A Miller; G Daudelin
Journal:  BMJ Innov       Date:  2016-04-15

5.  The institutional workers of biomedical science: Legitimizing academic entrepreneurship and obscuring conflicts of interest.

Authors:  Renata E Axler; Fiona A Miller; Pascale Lehoux; Trudo Lemmens
Journal:  Sci Public Policy       Date:  2017-11-06
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.